Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Huayu Lishui is a Traditional Chinese Medicine (TCM) formula developed by Huadong Hospital for the treatment of post-traumatic ankle bone marrow edema (BME). The formula is based on the therapeutic principles of supplementing Qi (Yiqi), resolving blood stasis (Huayu), and promoting diuresis to eliminate dampness (Lishui). It aims to improve local microcirculation, reduce intraosseous pressure, and accelerate the resolution of bone marrow lesions. Clinical research indicates that the formula helps alleviate pain and restore joint function by modulating inflammatory responses and promoting the absorption of edema fluid within the bone marrow. It is typically administered as an oral decoction or granule preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yiqi huayu lishui.